NCT00203060View on ClinicalTrials.gov

Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa

PHASE3CompletedINTERVENTIONAL

Enrollment

404

Participants

Timeline

Start Date

July 31, 1997

Primary Completion Date

July 31, 2000

Study Completion Date

July 31, 2000

Conditions

Parkinson's Disease

Interventions

DRUG

Rasagiline Mesylate

tablet, 1 or 2 mg, daily, 58 weeks

DRUG

placebo

tablet, once daily, 58 weeks

All Listed Sponsors

lead

Teva Neuroscience, Inc.

INDUSTRY